Plain-English translation of NCT07217392 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two new pacing leads — the Tendril STS and UltiPace — that work by pacing your heart from the left bundle branch area, which is a specific location in your heart's electrical system. These leads are designed to work with pacemakers, defibrillators, or cardiac resynchronization therapy devices. Researchers want to make sure this new approach is safe and effective for treating heart rhythm problems and heart failure over a 6-month period.
Traditional pacemakers pace the heart from the right side of the heart, but pacing from the left bundle branch area may provide better results for some patients with heart rhythm problems or heart failure. This trial will help doctors understand whether this new location for pacing is a safe and effective option.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive an implant procedure to place one of these new pacing leads in your heart. After the procedure, you will return to the clinic for follow-up visits and tests at regular intervals over 6 months to make sure the lead is working properly and to monitor your heart health. The research team will collect data from your device and perform heart-related exams during these visits.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Brazil
France
Germany
India